IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Baldwin Investment Management LLC

Baldwin Investment Management LLC lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,548 shares of the medical research company’s stock after purchasing an additional 280 shares during the period. Baldwin Investment Management LLC’s holdings in IQVIA were worth $841,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in IQV. Versant Capital Management Inc grew its position in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in IQVIA in the 2nd quarter valued at $27,000. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA in the 3rd quarter worth $27,000. Park Place Capital Corp purchased a new stake in IQVIA in the 3rd quarter valued at approximately $28,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the 2nd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $201.24 on Wednesday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm’s fifty day moving average price is $221.18 and its 200 day moving average price is $226.75. The company has a market capitalization of $36.53 billion, a price-to-earnings ratio of 26.41, a price-to-earnings-growth ratio of 2.10 and a beta of 1.51.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IQV. Robert W. Baird dropped their target price on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday, November 1st. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Friday, November 1st. Barclays reduced their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Truist Financial dropped their price objective on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.